State Drug Administration: 10 drug suspension recalls

10 drug deactivation recalls, including compound acetaminophen tablets, compound anti-aubergine hydroxide tablets... On 29 October, the State Drug Administration issued a Circular on non-compliance of 18 batches of medicines (No. 73 of 2020) (hereinafter referred to as "Notice").
notice shows that 18 batches of drugs produced by 11 pharmaceutical manufacturers, including Guizhou Yiyi Health Pharmaceutical Co., Ltd., have been inspected by nine drug testing institutions, including the Chongqing Food and Drug Inspection and Testing Research Institute.
These 18 batches of non-conforming drugs involved 10 kinds of drugs, there are 6 kinds of preparations, respectively, compound acetaminophen tablets, compound anti-eggplant aluminum hydroxide tablets, ginseng injection, injection of Ozagrain sodium, injection of sodium caroton, injection of nida platinum;
For the above non-compliant drugs, the drug supervision and administration department has asked the relevant enterprises and units to take risk control measures such as suspension of sales and use, recall, etc., to investigate the reasons for non-compliance and to carry out effective rectification.
same time, the State Drug Administration requires the relevant provincial drug regulatory departments to organize investigations into illegal acts committed by the above-mentioned enterprises and units in the production and sale of counterfeit and inferior drugs in accordance with the Drug Administration Law of the People's Republic of China, and to publicly investigate and punish the results in accordance with the provisions.